Inorganic nanoparticle-based advanced cancer therapies: Promising combination strategies.

Cancer drug delivery Cancer therapy Combination therapy Nanocarriers Nanoparticle drug delivery RNAi siRNA drug delivery

Journal

Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391

Informations de publication

Date de publication:
12 2022
Historique:
received: 22 12 2021
revised: 15 08 2022
accepted: 24 09 2022
pubmed: 2 10 2022
medline: 29 11 2022
entrez: 1 10 2022
Statut: ppublish

Résumé

Inorganic nanoparticles for drug delivery in cancer treatment offer many potential advantages because they can maximize therapeutic effect through targeting ligands while minimizing off-target side-effects through drug adsorption and infiltration. Although inorganic nanoparticles were introduced as drug carriers, they have emerged as having the capacity for combined therapeutic capabilities, including anticancer effects through cytotoxicity, suppression of oncogenes and cancer cell signaling pathway inhibition. The most promising advanced strategies for cancer therapy are as synergistic platforms for RNA interference (siRNA, miRNA, shRNA) and as synergistic drug delivery agents for the inhibition of cancer cell signaling pathways. The present work summarizes relevant current work, the promise of which is suggested by a projected compound annual growth rate of ∼ 20% for drug delivery alone.

Identifiants

pubmed: 36182068
pii: S1359-6446(22)00379-8
doi: 10.1016/j.drudis.2022.103386
pii:
doi:

Substances chimiques

Drug Carriers 0
RNA, Small Interfering 0

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

103386

Informations de copyright

Copyright © 2022. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Maria John Newton Amaldoss (MJN)

Adult Cancer Program, Lowy Cancer Research Centre, Prince of Wales Clinical School, UNSW Sydney, Sydney, NSW 2052, Australia; School of Materials Science and Engineering, UNSW Sydney, Sydney, NSW 2052, Australia. Electronic address: dr.mariajohnnewton@gmail.com.

Jia-Lin Yang (JL)

Adult Cancer Program, Lowy Cancer Research Centre, Prince of Wales Clinical School, UNSW Sydney, Sydney, NSW 2052, Australia.

Pramod Koshy (P)

School of Materials Science and Engineering, UNSW Sydney, Sydney, NSW 2052, Australia.

Ashwin Unnikrishnan (A)

Adult Cancer Program, Lowy Cancer Research Centre, Prince of Wales Clinical School, UNSW Sydney, Sydney, NSW 2052, Australia.

Charles C Sorrell (CC)

School of Materials Science and Engineering, UNSW Sydney, Sydney, NSW 2052, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH